MYO - Myomo Inc Stock Price, Fair Value and News

3.64USD-0.04 (-1.09%)Delayed

Market Summary

USD3.64-0.04

Delayed

-1.09%

MYO Stock Price

View Fullscreen

MYO RSI Chart

MYO Valuation

Market Cap

104.9M

Price/Earnings (Trailing)

-11.23

Price/Sales (Trailing)

5.37

EV/EBITDA

-11.08

Price/Free Cashflow

-13.51

MYO Price/Sales (Trailing)

MYO Profitability

Operating Margin

67.39%

EBT Margin

-46.77%

Return on Equity

-85.68%

Return on Assets

-56.53%

Free Cashflow Yield

-7.4%

MYO Fundamentals

MYO Revenue

Revenue (TTM)

19.5M

Rev. Growth (Yr)

8.93%

Rev. Growth (Qtr)

-21.07%

MYO Earnings

Earnings (TTM)

-9.3M

Earnings Growth (Yr)

-45.05%

Earnings Growth (Qtr)

-55.91%

Breaking Down MYO Revenue

Last 7 days

-5.0%

Last 30 days

33.8%

Last 90 days

11.7%

Trailing 12 Months

682.8%

How does MYO drawdown profile look like?

MYO Financial Health

Current Ratio

2.83

MYO Investor Care

Shares Dilution (1Y)

37.71%

Diluted EPS (TTM)

-0.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	19.5M	0	0	0
2023	15.1M	17.4M	18.5M	19.2M
2022	15.4M	16.0M	15.5M	15.6M
2021	8.9M	11.2M	13.6M	13.9M
2020	4.0M	4.0M	5.3M	7.6M
2019	3.0M	3.2M	3.2M	3.8M
2018	1.7M	2.0M	2.1M	2.4M
2017	1.2M	1.3M	1.4M	1.6M
2016	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Myomo Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	kovelman harry	sold (taxes)	-560	3.84	-146	chief medical officer
Apr 03, 2024	kovelman harry	sold (taxes)	-433	2.97	-146	chief medical officer
Mar 14, 2024	kirk thomas f	bought	175,000	3.5	50,000	-
Mar 11, 2024	henry david a	sold (taxes)	-27,286	3.51	-7,774	chief financial officer
Mar 11, 2024	mitchell micah	sold (taxes)	-18,810	3.51	-5,359	chief commercial officer
Mar 11, 2024	kovelman harry	sold (taxes)	-23,130	3.51	-6,590	chief medical officer
Mar 05, 2024	kovelman harry	sold (taxes)	-570	3.88	-147	chief medical officer
Feb 05, 2024	kovelman harry	sold (taxes)	-468	3.21	-146	chief medical officer
Jan 19, 2024	morris milton mayo	acquired	95,000	3.8	25,000	-
Jan 03, 2024	kovelman harry	sold (taxes)	-680	4.69	-145	chief medical officer

Which funds bought or sold MYO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Clear Point Advisors Inc.	reduced	-99.92	-6,009	3.00	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-243,867	-	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	98.00	98.00	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-335,144	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	121	92,160	297,570	0.01%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-378,065	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-56,668	-	-%
May 15, 2024	MARSHALL WACE, LLP	reduced	-36.04	-285,907	204,898	-%
May 15, 2024	Engineers Gate Manager LP	sold off	-100	-84,048	-	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	19,620	19,620	-%

Are Funds Buying or Selling MYO?

Are funds buying MYO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MYO

No. of Funds

Unveiling Myomo Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	rosalind advisors, inc.	9.9%	2,447,740	SC 13G/A
Feb 14, 2024	rosalind advisors, inc.	9.2%	2,433,740	SC 13G/A
Feb 14, 2024	rosalind advisors, inc.	9.2%	2,433,740	SC 13G/A
Feb 14, 2024	packer paul	0.0%	0	SC 13G/A
Feb 07, 2024	hirschman orin	9.9%	2,838,290	SC 13G/A
Sep 07, 2023	hirschman orin	9.6%	2,540,000	SC 13G/A
Aug 31, 2023	triple gate partners, lp	9.36%	2,482,782	SC 13G/A
Aug 28, 2023	rosalind advisors, inc.	9.8%	2,611,418	SC 13G/A
Mar 28, 2023	strategic risk, llc.	5.1%	1,057,279	SC 13G
Feb 15, 2023	hewlett fund lp	780%	1e+06	SC 13G/A

Recent SEC filings of Myomo Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 15, 2024	144	Notice of Insider Sale Intent
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 06, 2024	4	Insider Trading
May 06, 2024	8-K	Current Report
May 03, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A

Peers (Alternatives to Myomo Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Myomo Inc News

Latest updates

Myomo Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-21.1%	3,754,389	4,756,383	5,079,523	5,958,544	3,446,708	4,041,527	3,968,201	3,677,575	3,867,926	4,031,634	4,383,957	3,104,294	2,336,489	3,789,976	1,926,660	858,590	1,008,145	1,520,696	606,619	880,349	830,066
Cost Of Revenue	-11.9%	1,455,345	1,651,522	1,590,675	1,677,488	1,139,074	1,408,842	1,331,217	1,276,444	1,290,704	909,175	1,110,204	901,566	623,152	1,007,524	855,338	418,862	318,651	424,646	329,227	380,093	286,802
Gross Profit	-26.0%	2,299,044	3,104,862	3,488,848	4,281,056	2,307,634	2,632,685	2,636,984	2,401,131	2,577,222	3,122,459	3,273,753	2,202,728	1,713,337	2,782,452	1,071,322	439,728	689,494	1,096,051	277,392	500,256	543,264
Operating Expenses	11.7%	6,187,811	5,538,055	5,513,217	5,384,062	4,978,599	4,856,862	5,455,625	5,296,960	5,315,953	5,828,190	5,304,024	4,802,360	4,645,769	4,469,063	3,616,423	3,288,275	4,111,921	3,676,867	3,102,440	3,206,600	3,226,059
S&GA Expenses	-100.0%	-	4,660,049	4,795,961	4,819,827	4,501,608	4,357,188	4,765,218	4,664,088	4,656,417	5,039,348	4,662,796	4,202,244	4,119,802	4,050,305	3,270,757	2,890,464	3,604,968	3,234,344	2,669,375	2,779,027	2,779,711
R&D Expenses	8.9%	956,215	878,006	717,256	564,235	476,991	499,674	690,407	632,872	659,536	788,842	641,228	600,116	525,967	418,758	345,666	397,811	506,953	442,523	433,065	427,573	446,348
EBITDA Margin	-12.9%	-0.46	-0.41	-0.40	-0.47	-0.67	-0.66	-0.69	-0.63	-0.63	-0.72	-0.66	-0.87	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,135	40,025	166,643	-	-	-	-
Income Taxes	16.0%	82,158	70,798	46,355	-3,562	42,411	-23,265	23,382	-6,435	76,255	22,324	22,696	15,665	28,243	-	1,153	1,085	613	-	-	-	-
Earnings Before Taxes	-57.1%	-3,753,474	-2,389,307	-1,982,660	-1,017,712	-2,601,884	-2,190,715	-2,806,334	-2,915,357	-2,738,679	-2,710,874	-2,034,326	-2,605,650	-2,932,551	-1,701,264	-2,775,418	-3,285,849	-3,801,380	-	-2,788,118	-2,565,327	-2,598,060
EBT Margin	-12.6%	-0.47	-0.42	-0.42	-0.49	-0.69	-0.68	-0.72	-0.65	-0.66	-0.74	-0.68	-0.90	-	-	-	-	-	-	-	-	-
Net Income	-55.9%	-3,835,632	-2,460,104	-2,029,016	-1,014,150	-2,644,295	-2,167,450	-2,829,716	-2,908,922	-2,814,934	-2,733,198	-2,057,022	-2,621,315	-2,960,794	-1,698,413	-2,776,571	-3,286,934	-3,801,993	-2,761,504	-2,788,118	-2,565,327	-2,598,060
Net Income Margin	-12.8%	-0.48	-0.42	-0.42	-0.50	-0.70	-0.69	-0.73	-0.66	-0.66	-0.75	-0.69	-0.90	-	-	-	-	-	-	-	-	-
Free Cashflow	-38.5%	-3,305,372	-2,387,410	-1,768,899	-300,496	-1,861,775	-2,467,606	-2,804,460	-2,700,790	-2,372,479	-1,852,468	-2,264,531	-3,599,961	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	13.3%	16,521	14,582	17,054	13,297	13,736	10,162	12,157	14,562	17,977	20,095	17,459	17,709	20,923	14,710	15,357	12,828	15,912	6,599	6,083	8,543	11,100
Current Assets	15.0%	15,705	13,651	16,042	12,630	12,912	9,215	11,052	13,305	16,605	19,092	16,461	16,632	19,929	14,446	15,176	12,643	15,566	6,149	5,703	8,167	10,719
Cash Equivalents	-20.9%	5,435	6,871	6,912	6,006	9,264	5,346	7,400	10,236	12,943	15,524	12,607	13,772	17,371	12,241	13,318	10,733	13,726	4,465	4,328	6,669	9,234
Inventory	32.3%	2,386	1,804	1,485	1,337	1,565	1,400	1,483	1,261	1,029	808	644	729	794	707	760	679	603	440	454	349	301
Net PPE	17.1%	206	176	172	154	191	194	240	283	280	275	302	320	210	95.00	106	110	139	155	170	193	173
Liabilities	0.5%	5,621	5,592	6,031	4,477	4,104	3,803	4,335	4,214	5,107	4,686	4,312	3,897	4,856	3,144	2,374	2,775	4,129	4,774	1,664	1,436	1,578
Current Liabilities	1.5%	5,557	5,477	5,778	4,337	3,934	3,602	4,114	3,884	4,653	4,283	3,723	3,220	4,097	2,870	2,207	2,688	4,128	3,884	1,663	1,436	1,578
Shareholder's Equity	21.3%	10,900	8,989	11,023	8,820	9,632	6,359	7,822	10,348	12,870	15,409	13,148	13,811	16,067	11,565	12,983	10,053	11,783	6,426	4,419	7,061	9,436
Retained Earnings	-4.0%	-100,766	-96,930	-94,470	-92,441	-91,427	-88,783	-86,615	-83,800	-80,877	-78,062	-75,329	-73,272	-70,650	-67,690	-65,991	-63,214	-59,927	-56,125	-53,364	-50,576	-48,011
Additional Paid-In Capital	5.4%	111,522	105,840	105,506	101,227	100,955	95,105	94,455	94,149	93,804	93,538	88,493	87,091	86,728	79,274	78,980	73,274	71,717	57,957	57,789	57,688	57,537
Shares Outstanding	6.1%	28,790	27,135	26,515	21,092	20,923	7,751	7,064	6,924	6,886	6,870	5,530	5,417	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	9,527	-	-	-	10,011	-	-	-	60,192	-	-	-	11,896	-	-	-	11,077	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-37.8%	-3,245	-2,355	-1,714	-285	-1,816	-2,464	-2,798	-2,648	-2,322	-1,828	-2,209	-3,396	-2,112	-1,132	-1,789	-3,665	-2,445	-2,644	-2,290	-2,287	-3,119
Share Based Compensation	-4.1%	320	334	330	280	171	273	306	345	266	265	302	363	166	203	182	106	123	168	147	386	208
Cashflow From Investing	-254.4%	-3,542	2,294	-1,315	-2,963	-45.08	-3.38	-5.74	-52.79	-248	-23.93	-54.88	-203	-44.49	-15.46	-22.42	-	-7.88	-13.73	-3.36	-29.50	-5.40
Cashflow From Financing	17296380.6%	5,362	31*	3,950	-8.15	5,772	377	-	-	-	4,780	1,099	1.00	7,288	19.00	4,375	673	11,714	2,795	-46.88	-247	5,818

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MYO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 3,754,389	$ 3,446,708
Cost of revenue	1,455,345	1,139,074
Gross profit	2,299,044	2,307,634
Operating expenses:
Research and development	956,215	476,991
Selling, clinical and marketing	2,361,845	2,030,551
General and administrative	2,869,751	2,471,057
Total operating expenses	6,187,811	4,978,599
Loss from operations	(3,888,767)	(2,670,965)
Other (income) expense, net
Interest income, net	(135,293)	(86,314)
Other expense, net	0	31
Loss on equity investment	0	17,202
Total other expense (income), net	(135,293)	(69,081)
Loss before income taxes	(3,753,474)	(2,601,884)
Income tax expense	82,158	42,411
Net loss	$ (3,835,632)	$ (2,644,295)
Weighted average number of common shares outstanding:
Basic	36,752,597	24,196,732
Diluted	36,752,597	24,196,732
Net loss per share attributable to common stockholders
Basic	$ (0.1)	$ (0.11)
Diluted	$ (0.1)	$ (0.11)
Product revenue
Revenue	$ 3,754,389	$ 3,446,708

MYO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 5,434,726	$ 6,871,306
Short-term investments	5,523,664	1,994,662
Accounts receivable, net	1,683,414	2,382,658
Inventories, net	2,386,497	1,803,507
Prepaid expenses and other current assets	676,787	598,850
Total Current Assets	15,705,088	13,650,983
Operating lease assets with right of use, net	604,897	663,554
Equipment, net	205,917	175,794
Other assets	4,955	91,237
Total Assets	16,520,857	14,581,568
Current Liabilities:
Accounts payable and accrued expenses	4,963,707	4,885,944
Current operating lease liability	421,514	486,143
Income taxes payable	171,280	96,461
Deferred revenue	0	8,510
Total Current Liabilities	5,556,501	5,477,058
Non-current operating lease liability	64,599	115,160
Total Liabilities	5,621,100	5,592,218
Commitments and Contingencies	0	0
Stockholders’ Equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock par value $0.0001 per share, 65,000,000 shares authorized; 28,789,823 and 27,135,061 shares issued as of March 31, 2024 and December 31, 2023, respectively; and 28.789,796 and 7,135,034 shares outstanding at March 31, 2024 and December 31, 2023, respectively	2,881	2,715
Additional paid-in capital	111,522,270	105,840,239
Accumulated other comprehensive income	147,511	83,669
Accumulated deficit	(100,766,441)	(96,930,809)
Treasury stock, 27 shares at cost	(6,464)	(6,464)
Total Stockholders’ Equity	10,899,757	8,989,350
Total Liabilities and Stockholders’ Equity	$ 16,520,857	$ 14,581,568

About Myomo Inc

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, China, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, rehabilitation hospitals and surgery centers, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

CEO	Mr. Paul R. Gudonis
WEBSITE	https://myomo.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	100

Myomo Inc Frequently Asked Questions

What is the ticker symbol for Myomo Inc? What does MYO stand for in stocks?

MYO is the stock ticker symbol of Myomo Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Myomo Inc (MYO)?

As of Fri May 17 2024, market cap of Myomo Inc is 104.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MYO stock?

You can check MYO's fair value in chart for subscribers.

What is the fair value of MYO stock?

You can check MYO's fair value in chart for subscribers. The fair value of Myomo Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Myomo Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MYO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Myomo Inc a good stock to buy?

The fair value guage provides a quick view whether MYO is over valued or under valued. Whether Myomo Inc is cheap or expensive depends on the assumptions which impact Myomo Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MYO.

What is Myomo Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MYO's PE ratio (Price to Earnings) is -11.23 and Price to Sales (PS) ratio is 5.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MYO PE ratio will change depending on the future growth rate expectations of investors.